PharmaJet’s Tropis system is now the exclusive intradermal delivery system for two authorized novel COVID-19 vaccines. They include:
- The world’s first plasmid DNA COVID-19 vaccine for administration in humans from Zydus Lifesciences (ZyCoV-D), is exclusively delivered with Tropis based on preclinical and clinical study results that showed increased immune response of the vaccine translating into clinical effectiveness of ZyCoV-D.
- The world’s first self-amplifying mRNA-based Omicron-specific COVID-19 booster vaccine from Gennova Biopharmaceuticals (GEMCOVAC-OM) to achieve emergency use authorization, allows a low dose of the first room temperature stable mRNA vaccine.
Tropis ID has already been used for millions of injections in multiple immunization campaigns worldwide. Data has repeatedly shown improved immunogenicity for nucleic acid vaccines and therapeutics, compared with needle and syringe and electroporation delivery.
This improved immunogenicity translated into efficacy demonstrated for the DNA vaccine, ZyCov-D, and to non-inferior immune response to COVISHIELD for the GEM-COVAC-OM samRNA vaccine.
“This marks an important milestone for PharmaJet in that we now have two commercially available nucleic acid-based vaccines in India being exclusively delivered with the Tropis Precision Delivery System,” Chris Cappello, president and CEO of closely-held PharmaJet, said in a statement.
He said the company is committed to supporting the advancement of mRNA and DNA vaccines targeting a variety of infectious disease applications for global public health benefit.
